Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.35 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944698 | 0.73 | MAPK14 (0.50) | MAPK1 | |
| SCHEMBL2949210 | 0.67 | ABL1 (0.40) | SCN9A | |
| SCHEMBL2954098 | 0.67 | S1PR2 (0.39) | SCN9A | |
| SCHEMBL2954669 | 0.67 | SCN9A (0.46) | MAPK1SCN9A | |
| SCHEMBL2951647 | 0.65 | MAPK14 (0.40) | SCN9A | |
| SCHEMBL2953480 | 0.62 | MAPK14 (0.53) | — | |
| SCHEMBL2948274 | 0.61 | MAPK14 (0.54) | SCN9A | |
| SCHEMBL2952776 | 0.61 | MAPK14 (0.54) | SCN9A | |
| SCHEMBL2953194 | 0.60 | MAPK14 (0.50) | SCN9A | |
| SCHEMBL2951418 | 0.60 | MAPK14 (0.68) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | claimed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | claimed |
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | MAP3K12 15/4885MAPK1 111/4885GRM4 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.